Trials / Completed
CompletedNCT02013050
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Soligenix · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGX942 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2015-12-01
- Completion
- 2016-09-01
- First posted
- 2013-12-17
- Last updated
- 2017-08-28
- Results posted
- 2017-07-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02013050. Inclusion in this directory is not an endorsement.